EVOK Evoke Pharma Inc.

2.47
-0.05  -2%
Previous Close 2.52
Open 2.53
Price To Book 20.58
Market Cap 61,015,397
Shares 24,702,590
Volume 622,466
Short Ratio
Av. Daily Volume 348,931
Stock charts supplied by TradingView

NewsSee all news

  1. Evoke Receives FDA Conditional Acceptance of Gimoti Brand Name Following NDA Resubmission

    SOLANA BEACH, Calif., May 20, 2020 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that the U.S. Food

  2. Evoke Pharma Reports First Quarter 2020 Financial Results and Changes its 2020 Annual Meeting of Stockholders to a Virtual Format

    Gimoti™ Prescription Drug User Fee Act (PDUFA) date is June 19, 2020 SOLANA BEACH, Calif., May 12, 2020 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments

  3. Evoke Pharma Reports Fourth Quarter and Full Year 2019 Financial Results

    SOLANA BEACH, Calif., March 12, 2020 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced its financial

  4. Evoke Pharma Receives Notice of Allowance from USPTO for Gimoti™

    SOLANA BEACH, Calif., Jan. 27, 2020 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that the United

  5. Evoke Pharma Enters Commercialization Agreement with EVERSANA Life Sciences for Gimoti™

    EVERSANA to commercialize and distribute Gimoti in the U.S. EVERSANA to provide $5 million revolving credit facility upon FDA approval SOLANA BEACH, Calif. and CHICAGO, Jan. 23, 2020 (GLOBE NEWSWIRE) -- Evoke

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

CRL issued April 2, 2019. NDA resubmitted with new PDUFA date of June 19, 2020.
Gimoti - EVK-001
Female diabetic gastroparesis

Latest News

  1. Evoke Receives FDA Conditional Acceptance of Gimoti Brand Name Following NDA Resubmission

    SOLANA BEACH, Calif., May 20, 2020 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that the U.S. Food

  2. Evoke Pharma Reports First Quarter 2020 Financial Results and Changes its 2020 Annual Meeting of Stockholders to a Virtual Format

    Gimoti™ Prescription Drug User Fee Act (PDUFA) date is June 19, 2020 SOLANA BEACH, Calif., May 12, 2020 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments

  3. Evoke Pharma Reports Fourth Quarter and Full Year 2019 Financial Results

    SOLANA BEACH, Calif., March 12, 2020 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced its financial

  4. Evoke Pharma Receives Notice of Allowance from USPTO for Gimoti™

    SOLANA BEACH, Calif., Jan. 27, 2020 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that the United

  5. Evoke Pharma Enters Commercialization Agreement with EVERSANA Life Sciences for Gimoti™

    EVERSANA to commercialize and distribute Gimoti in the U.S. EVERSANA to provide $5 million revolving credit facility upon FDA approval SOLANA BEACH, Calif. and CHICAGO, Jan. 23, 2020 (GLOBE NEWSWIRE) -- Evoke

  6. FDA Accepts Evoke Pharma's NDA Resubmission for Gimoti™

    SOLANA BEACH, Calif., Jan. 21, 2020 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on the development of drugs to treat gastrointestinal (GI) disorders and diseases,

  7. Evoke Resubmits Gimoti™ New Drug Application to FDA

    SOLANA BEACH, Calif., Dec. 20, 2019 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it has

  8. Evoke Pharma Regains Compliance with Nasdaq Minimum Bid Requirement

    SOLANA BEACH, Calif., Dec. 02, 2019 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that on November

  9. Evoke Pharma Granted 180-Day Extension by Nasdaq Regarding Minimum Bid Price

    SOLANA BEACH, Calif., Nov. 13, 2019 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that on November

  10. Evoke Pharma Reports Third Quarter 2019 Financial Results

    SOLANA BEACH, Calif., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced its financial

  11. Evoke Pharma Completes Manufacturing of Commercial Scale Registration Batches of Gimoti™

    SOLANA BEACH, Calif., Sept. 17, 2019 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it has